US Pre-emption ruling could damage innovation says HIMA
This article was originally published in Clinica
Executive Summary
In a decision that could adversely affect every US medical device manufacturer, all nine judges of the US Supreme Court on June 26th agreed that the FDA's imprimatur does not protect companies from product liability suits in state courts. In their review of the legal arguments in the Medtronic vs Lohr case, in which the plaintiff is seeking damages for an allegedly faulty pacemaker lead, the judges ruled against Medtronic's pre-emption claims of 510(k) products covered under FDA regulation (see Clinica No 703, p 7).
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.